EXPANSION OF THE ALPHA-2-ADRENERGIC RECEPTOR FAMILY - CLONING AND CHARACTERIZATION OF A HUMAN ALPHA-2-ADRENERGIC RECEPTOR SUBTYPE, THE GENE FOR WHICH IS LOCATED ON CHROMOSOME-2
EXPANSION OF THE ALPHA-2-ADRENERGIC RECEPTOR FAMILY - CLONING AND CHARACTERIZATION OF A HUMAN ALPHA-2-ADRENERGIC RECEPTOR SUBTYPE, THE GENE FOR WHICH IS LOCATED ON CHROMOSOME-2
复制标题
DOI：
10.1073/pnas.87.13.5094
复制
发表时间：
1990-07-01
影响因子：
11.1
通讯作者：
LEFKOWITZ, RJ
中科院分区：
文献类型：
--
作者：
LOMASNEY, JW;LORENZ, W;LEFKOWITZ, RJ
药理学、生物化学和遗传学分析表明存在多个α。2-肾上腺素能受体（α - 2ar）亚型。我们克隆了一个人类。阿尔法。利用聚合酶链反应与先前克隆的. α的保守区同源的寡核苷酸引物进行鉴定。2ar，位于人类染色体4 （C4）和10c（10）上的基因。推导出的氨基酸序列编码了一种由450个氨基酸组成的蛋白质，其推测的拓扑结构与鸟嘌呤核苷酸结合蛋白偶联受体家族相似，但其结构与。alpha. 2ar最接近。竞争曲线分析了COS-7细胞中表达的受体与多种肾上腺素能配体的结合特性，显示出独特的。α。2基于“增大化现实”技术的药理学。与体细胞杂交表明该受体的基因位于染色体2上。Northern blot分析显示大鼠各组织在肝脏和肾脏均有表达。该受体独特的药理学和组织定位表明，这是一个。以前未被经典药理学或配体结合方法鉴定的2AR亚型。
Pharmacologic, biochemical, and genetic analyses have demonstrated the existence of multiple .alpha.2-adrenergic receptor (.alpha.2AR) subtypes. We have cloned a human .alpha.2AR by using the polymerase chain reaction with oligonucleotide primers homologous to conserved regions of the previously cloned .alpha.2ARs, the genes for which are located on human chromosomes 4 (C4) and 10 C(10). The deduced amino acid sequence encodes a protein of 450 amino acids whose putative topology is similar to that of the family guanine nucleotide-binding protein-coupled receptors, but whose structure most closely resembles that of the .alpha.2ARs. Competition curve analysis of the binding properties of the receptor expressed in COS-7 cells with a variety of adrenergic ligands demonstrates a unique .alpha.2AR pharmacology. Hybridization with somatic cell hybrids shows that the gene for this receptor is located on chromosome 2. Northern blot analysis of various rat tissues shows expression in liver and kidney. The unique pharmacology and tissue localization of this receptor suggest that this is an .alpha.2AR subtype not previously identified by classical pharmacological or ligand binding approaches.